how many people are on glp-1 drugs trends 2025: real-world data, patient outcomes & future therapies Overview of GLP-1s
Description
The result is a patchwork of coverage policies across all 50 states
Further speeding up adoption are rising awareness of lifestyle-related illnesses and increased acceptance of GLP-1 treatments for conditions other than diabetes, such as obesity
May your doses stay well-tolerated, your mind stay clear, and your progress stay steady.
HankoskyERWangHNeffLMKanHWangFAhmadNNet al
As of publication, Ozempic and Mounjaro are not approved by the FDA for weight loss or weight management (though clinicians sometimes prescribe these drugs for such off-label uses)
